How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting...

14

Transcript of How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting...

Page 1: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 2: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 3: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 4: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 5: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 6: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 7: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 8: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 9: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 10: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 11: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 12: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 13: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Page 14: How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Altered Immune Responses in Rhesus Macaques Co-Infected with SIV and Plasmodium cynomolgi: An Animal Model for Coincident AIDS and Relapsing Malaria

Altered Immune Responses in Rhesus Macaques Co-Infected with SIV and Plasmodium cynomolgi: An Animal Model for Coincident AIDS and Relapsing Malaria

Spatiotemporal distribution of white matter lesions in relapsing–remitting and secondary progressive multiple sclerosis

Spatiotemporal distribution of white matter lesions in relapsing–remitting and secondary progressive multiple sclerosis

Tumor necrosis factor α and its receptors in relapsing-remitting multiple sclerosis

Tumor necrosis factor α and its receptors in relapsing-remitting multiple sclerosis

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

Fingolimod - Sociedade Portuguesa de Neurologia

Fingolimod - Sociedade Portuguesa de Neurologia

The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing–remitting multiple sclerosis

The relationship between regional microstructural abnormalities of the corpus callosum and physical and cognitive disability in relapsing–remitting multiple sclerosis

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis

Migrants' Remitting beyond Altruism and Self-Interest

Migrants' Remitting beyond Altruism and Self-Interest

Memory B cells from a subset of treatment naïve relapsing remitting multiple sclerosis patients elicit CD4+T cell proliferation and IFN-γ production in response to MBP and MOG

Memory B cells from a subset of treatment naïve relapsing remitting multiple sclerosis patients elicit CD4+T cell proliferation and IFN-γ production in response to MBP and MOG

Caudate nuclei volume, diffusion tensor metrics, and T 2 relaxation in healthy adults and relapsing-remitting multiple sclerosis patients: Implications for understanding gray matter

Caudate nuclei volume, diffusion tensor metrics, and T 2 relaxation in healthy adults and relapsing-remitting multiple sclerosis patients: Implications for understanding gray matter

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing‐remitting multiple sclerosis

Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing‐remitting multiple sclerosis

How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?

How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?

Ocrelizumab for treating relapsing multiple sclerosis

Ocrelizumab for treating relapsing multiple sclerosis

Compromised CD4 +  CD25 high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and

Compromised CD4 +  CD25 high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and

Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis

Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis